Circulating ferroptosis-related markers, particularly in combination, provide strong diagnostic value for ED and reflect disease severity. GPX4, SLC7A11, and ACSL4 may serve as promising biomarkers and potential therapeutic targets for ED management.
Xu et al. (Fri,) studied this question.